COVID-19
Read Time: 3 mins

SARS-CoV-2 Vaccine Immunogenicity in Patients with Autoimmune Inflammatory Rheumatic Diseases

Published Online: December 8th 2022 touchREVIEWS in RMD. 2022;1(2):38–9
Quick Links:
Article
Article Information
Article:

While the efficacy of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in preventing serious disease is well documented, studies are now emerging in immunosuppressed individuals. Among these are studies on the vaccination response in individuals with autoimmune inflammatory rheumatic diseases who take immunosuppressant therapies.

In this expert interview, Dr Victoria Furer from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, discusses the findings of her recent study, which were presented at the European Congress of Rheumatology (EULAR 2022), 1–4 June 2022.1

Q. What is known about the immune response to SARS-CoV-2 vaccination in patients with autoimmune inflammatory rheumatic diseases, and what questions remain unanswered?

The decline in anti-spike antibody levels after two doses of the BNT162b2 mRNA (Pfizer, New York, NY, USA) vaccine has been confirmed in the general population in several studies.2,3 However, there is a need for further studies on immunosuppressed individuals, including those with rheumatic disease.

Q. What were the aims and design of your study?

The primary aim of our study was to investigate the kinetics of the immune response to the BNT162b2 mRNA vaccine after the second and third vaccine doses in adult patients with autoimmune inflammatory rheumatic diseases compared with an immunocompetent population. The follow-up was up to 6 months after the second dose and 2–6 weeks after the third dose. The secondary aims were to evaluate the effect of immunosuppressive treatment on vaccine immunogenicity and the efficacy of the vaccination. This was a multicentre (three centres), longitudinal study that was launched at the time of the approval of coronavirus disease 2019 vaccinations in Israel. We enrolled 729 patients with rheumatic diseases and 122 immunocompetent control participants who were willing to undergo vaccination and follow-up.

Q. What were the findings in terms of humoral response?

At 6 weeks after the second vaccine dose, there was a full antibody response in immunocompetent participants and an adequate response (86%) in patients with rheumatic diseases. Among the 682 patients with rheumatic diseases and 116 control participants who completed the 6-month follow-up, there was a waning of antibody response in both groups. There were detectable levels of antibodies in 96% of the immunocompetent participants compared with 74% of the patients with rheumatic diseases. Among the participants vaccinated with the booster dose, the seropositivity rate increased to 82% following the third vaccine dose compared with 100% among the controls.

Q. What was the impact of the therapies on the vaccine‘s immunogenicity?

Most anti-cytokine therapies do not prevent the antibody response to the vaccination. The use of rituximab was the main risk factor for the lack of response to the vaccine. However, among patients treated with rituximab, one-third of patients who were seronegative prior to the booster vaccination had a response to the vaccine. Other factors associated with a lower vaccine response include treatment with glucocorticoids, mycophenolate motil (CellCept®; Genentech, South San Francisco, CA, USA) and abatercept. All patients treated with mycophenolate motil and abatercept responded to the booster vaccine. In a group of patients who were treated with rituximab, we also evaluated cellular immune response prior to and after the booster dose, and the cellular response was preserved in patients who did not develop any antibody response. This finding has been confirmed in several other studies.4,5

Q. On the basis of these findings, what are your recommendations for patients with autoimmune inflammatory rheumatic diseases?

It is important to emphasize that our study took place in October 2021, which was before the surge of the Omicron variant in Israel; therefore, the data cannot be applied to the Omicron cases. Our study supports the current recommendations by both the European Alliance of Associations for Rheumatology and the American College of Rheumatology, which support the use of booster vaccination in individuals susceptible to infection. Although unrelated to our study, we recommend the use of passive vaccination in patients treated with rituximab or in other heavily immunosuppressed individuals.

Dr Victoria Furer

Dr Victoria Furer is a specialist in internal medicine and rheumatology and lecturer at the Sackler Faculty of Medicine, Tel Aviv University, Israel. She works as a senior rheumatologist at the Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel. Dr Furer’s research has focused on vaccination in patients with rheumatic diseases.

Article Information:
Disclosure

Victoria Furer has no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article is an opinion piece and does not report on new clinical data, or any studies with human or animal subjects performed by the author.

Review Process

This is an expert interview and as such has not undergone the journal’s standard peer review process.

Authorship

The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.

Correspondence

Victoria Furer, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel-Aviv, 64239, Israel. E: furer.rheum@gmail.com

Support

No funding was received in the publication of this article.

Access

This article is freely accessible at touchIMMUNOLOGY.com © Touch Medical Media 2022

Acknowledgements

Medical writing support was provided by Katrina Mountfort, freelance medical writer, and funded by Touch Independent Medical Education.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.

Received

2022-11-01

References

  1. Furer V, Eviatur T, Freund T, et al. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: A longitudinal multicentre study. Ann Rheum Dis. 2022;81:1594–602.
  2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15.
  3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.
  4. Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis.2021;80:1345–50.
  5. Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: A prospective, cohort study. Lancet Rheumatol. 2022;4:e177–87.

Further Resources

Share this Article
Related Content In COVID-19
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72